Cargando…

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

Several COVID-19 vaccines have recently gained authorization for emergency use. Limited knowledge on duration of immunity and efficacy of these vaccines is currently available. Data on other coronaviruses after natural infection suggest that immunity to SARS-CoV-2 might be short-lived, and prelimina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roozendaal, Ramon, Solforosi, Laura, Stieh, Daniel J., Serroyen, Jan, Straetemans, Roel, Dari, Anna, Boulton, Muriel, Wegmann, Frank, Rosendahl Huber, Sietske K., van der Lubbe, Joan E. M., Hendriks, Jenny, Le Gars, Mathieu, Dekking, Liesbeth, Czapska-Casey, Dominika N., Guimera, Nuria, Janssen, Sarah, Tete, Sarah, Chandrashekar, Abishek, Mercado, Noe B., Yu, Jingyou, Koudstaal, Wouter, Perez-Ruixo, Juan J., Sadoff, Jerry, Barouch, Dan H., Schuitemaker, Hanneke, Zahn, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497464/ https://www.ncbi.nlm.nih.gov/pubmed/34620860 http://dx.doi.org/10.1038/s41467-021-26117-x

Ejemplares similares

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
por: Tiemessen, Machteld M., et al.
Publicado: (2022)

Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
por: Dari, Anna, et al.
Publicado: (2022)

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
por: Dari, Anna, et al.
Publicado: (2023)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
por: Solforosi, Laura, et al.
Publicado: (2023)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
por: McLean, Chelsea, et al.
Publicado: (2023)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
por: Tostanoski, Lisa H., et al.
Publicado: (2022)

Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
por: van der Lubbe, Joan E. M., et al.
Publicado: (2021)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP
por: Solforosi, Laura, et al.
Publicado: (2021)

Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice
por: Kil, Laurens P., et al.
Publicado: (2019)

Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
por: He, Xuan, et al.
Publicado: (2021)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
por: He, Xuan, et al.
Publicado: (2022)

Approaches and Challenges in SARS-CoV-2 Vaccine Development
por: Dagotto, Gabriel, et al.
Publicado: (2020)

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
por: Mahrokhian, Shant H., et al.
Publicado: (2022)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
por: Sadoff, Jerald, et al.
Publicado: (2021)

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations
por: Salisch, N. C., et al.
Publicado: (2019)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant
por: Liu, Jinyan, et al.
Publicado: (2022)

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
por: Liu, Jinyan, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
por: Swart, Maarten, et al.
Publicado: (2023)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts
por: Collier, Ai-ris Y., et al.
Publicado: (2021)

Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
por: Nkolola, Joseph P., et al.
Publicado: (2022)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
por: Yu, Jingyou, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
por: Jacob-Dolan, Catherine, et al.
Publicado: (2023)

Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bmasgq3116k4a8krfch7vmm8g5